NPPA Directs Price Reduction on Three Anti-Cancer Drugs Following Tax Exemptions
New Delhi: In a significant step toward making cancer treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to lower the Maximum Retail Price (MRP) of three key anti-cancer drugs: Trastuzumab, Osimertinib, and Durvalumab. This directive, issued through an official memorandum (O.M.) dated October 28, 2024, is aligned with the government’s commitment…
